NZ701000B2 - Novel melanoma antigen peptide and uses thereof - Google Patents
Novel melanoma antigen peptide and uses thereof Download PDFInfo
- Publication number
- NZ701000B2 NZ701000B2 NZ701000A NZ70100012A NZ701000B2 NZ 701000 B2 NZ701000 B2 NZ 701000B2 NZ 701000 A NZ701000 A NZ 701000A NZ 70100012 A NZ70100012 A NZ 70100012A NZ 701000 B2 NZ701000 B2 NZ 701000B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- peptide
- melanoma
- seq
- antigen peptide
- meloe
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 136
- 108091007172 antigens Proteins 0.000 title claims abstract description 136
- 102000038129 antigens Human genes 0.000 title claims abstract description 136
- 206010025650 Malignant melanoma Diseases 0.000 title claims abstract description 130
- 201000001441 melanoma Diseases 0.000 title claims abstract description 130
- 150000001413 amino acids Chemical group 0.000 claims abstract description 46
- 230000002265 prevention Effects 0.000 claims abstract description 14
- 210000004027 cells Anatomy 0.000 claims description 123
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 66
- 108090001123 antibodies Proteins 0.000 claims description 49
- 102000004965 antibodies Human genes 0.000 claims description 49
- 235000001014 amino acid Nutrition 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 30
- 108020001507 fusion proteins Proteins 0.000 claims description 18
- 102000037240 fusion proteins Human genes 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 15
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 11
- 239000004474 valine Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- 229960000310 ISOLEUCINE Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 5
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 230000004936 stimulating Effects 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 47
- 108090000765 processed proteins & peptides Proteins 0.000 description 47
- 230000004044 response Effects 0.000 description 35
- 210000004443 Dendritic Cells Anatomy 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 13
- 210000004698 Lymphocytes Anatomy 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102000027675 major histocompatibility complex family Human genes 0.000 description 11
- 108091007937 major histocompatibility complex family Proteins 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 210000003171 Lymphocytes, Tumor-Infiltrating Anatomy 0.000 description 10
- 102210010948 HLA-DQB1*0201 Human genes 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102100006400 CSF2 Human genes 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000000240 adjuvant Effects 0.000 description 6
- 108091006028 chimera Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102100005617 HLA-DQB1 Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 210000002966 Serum Anatomy 0.000 description 5
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 5
- -1 form amine hydrochlorides Chemical class 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 210000001616 Monocytes Anatomy 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 230000035492 administration Effects 0.000 description 4
- 230000000259 anti-tumor Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000010192 crystallographic characterization Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000010212 intracellular staining Methods 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 3
- 102000026088 HLA-A2 Antigen Human genes 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000007759 RPMI Media 1640 Substances 0.000 description 3
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 3
- 102100009534 TNF Human genes 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001464 adherent Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 108010007539 Blocking Antibodies Proteins 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101700059319 HD3B Proteins 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006822 Human Serum Albumin Proteins 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- 102100008857 MLANA Human genes 0.000 description 2
- 229920002521 Macromolecule Polymers 0.000 description 2
- 210000002752 Melanocytes Anatomy 0.000 description 2
- 241001482085 Meloe Species 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 210000000447 Th1 Cells Anatomy 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000000735 allogeneic Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 108020000411 toll-like receptors Proteins 0.000 description 2
- 102000002689 toll-like receptors Human genes 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- WHJKCPTVEYZNOG-UHFFFAOYSA-N 6-(hydroxymethyl)-5-methoxy-2-[4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane-3,4-diol Chemical group COCC1OC(OC)C(OC)C(OC)C1OC1C(O)C(O)C(OC)C(CO)O1 WHJKCPTVEYZNOG-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000432074 Adeno-associated virus Species 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710035186 BoLA-DQB Proteins 0.000 description 1
- 210000004899 C-terminal region Anatomy 0.000 description 1
- 102100003268 CD14 Human genes 0.000 description 1
- 101700027514 CD14 Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 210000004408 Hybridomas Anatomy 0.000 description 1
- 229940042795 Hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 210000002510 Keratinocytes Anatomy 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N Mannan Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 241001608711 Melo Species 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000004897 N-terminal region Anatomy 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229950008679 Protamine sulfate Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 230000027526 T cell tolerance induction Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 230000035531 V beta Effects 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic Effects 0.000 description 1
- 230000003127 anti-melanomic Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000000139 costimulatory Effects 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 150000008271 glucosaminides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper T lymphocyte Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002998 immunogenetic Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 230000002601 intratumoral Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-J lipid A(4-) Chemical compound O1[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O1 GZQKNULLWNGMCW-PWQABINMSA-J 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic Effects 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000027317 positive regulation of immune response Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
Abstract
The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 5 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient. the invention for use in the prevention or the treatment of melanoma in patient.
Description
NOVEL MELANOMA ANTIGEN E AND USES THEREOF
FIELD OF THE INVENTION:
The present invention relates to a melanoma antigen peptide comprising the amino
acids sequence selected in the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID
N023, SEQ ID N024 or SEQ ID NO:5 or a on-conservative variant thereof. Moreover
the invention also relates to a melanoma antigen peptide according to the invention for use in
the prevention or the treatment ofmelanoma in patient.
BACKGROUND OF THE INVENTION:
In antitumor immune ses, CD8 cytotoxic T cytes (CTL) have been
identified as the most powerful effector cells (Vesely MD et al., 2011). As a consequence,
most previous anti-cancer vaccines use class I HLA—restricted peptides derived from tumor
antigens in order to ate CTL responses. r, the clinical impact of peptide-based
cancer vaccines remains still modest, even if a recent gplOO-derived peptide vaccination was
shown to increase patient survival in melanoma berg SA et al., 2004 and
tzentruber DJ et al., 2011). In addition to a variety of immune suppressive mechanisms
originating from the tumor , suboptimal design of vaccines used so far may explain this
failure. In particular, short epitopic peptides, could induce vanishing CTL responses or
tolerance s targeted antigens (Bijker MS et al., 2007 and Toes RE et al., 1996). In the
meanwhile, CD4 helper T cells have gained interest in anti-tumor immunity and
therapy. Indeed, tumor-reactive CD4+ T helper 1 T cells (Th1) produce several
cytokines (such as IFN-y, TNF-d and IL-2) essential for the ion of cell-mediated
immunity against tumors. One widely accepted model demonstrates the ability of CD4+ T
cells to ‘license’ dendritic cells (DCs) for efficient CD8+ T cell priming through the
interaction of costimulatory receptors (Bennett SR et al., 1998 and Smith CM et al., 2004).
The cytokines secreted by CD4+ Th1 cells also exert direct antitumor and antiangiogenic
effects. Furthermore, it has been demonstrated in a mouse model that only tumor-reactive
CD4+ T cells have been found to ensure efficient effector CTLs recruitment at the tumor site.
In a al standpoint, a high density of tumor-infiltrating CD4+ Th1 cells has been recently
shown as a good prognostic marker in colorectal cancer patients emphasizing the role of these
cells in cancer immunosurveillance. In melanoma, tumor-reactive CD4 T cells have also been
ated with a good clinical outcome (Robbins PF et al., 2002), and more recently the same
group showed that tumor specific CD4 T cells were present in at least 20% of metastatic
melanomas, and suggested that the infiision of TIL populations containing CD4 specific T
cells could enhance the efficacy of adoptive cell y (Friedman KM et al., 2012). In the
same line of thought, it has been demonstrated in a melanoma patient that the adoptive cell
transfer of CD4 T cells specific for NYESO-l antigen induces durable clinical remission and
led to endogenous responses against non-targeted tumor antigens, suggesting the stimulation
of immune responses by transferred CD4 T cells (Hunder NN et al., 2008).
In the field of peptide vaccination, it has been documented twenty years ago, in a
mouse model that the generation of a strong CD8 response against a LCMV-derived peptide
ed on the ce of CD4 helper T cells (Fayolle C et al., 1991). These results have
been more recently confirmed in a al setting by the use of synthetic long peptides (SLP)
in ctal cancer, using P53 derived SLP (Speetjens FM et al., 2009), in vulvar
intraepithelial neoplasia (Kenter GG et al., 2009) and cervical cancer patients (Welters MJ et
al., 2008) using HPVlé-derived SLP. In the case of vulvar neoplasia, clinical responses
ed to be ated with the induction of strong HPV16 specific immune responses.
Synthetic long peptides containing immunogenic CD8 and CD4 tumor epitopes are therefore
attractive tools to implement therapeutic cancer e.
One of the main issues in the field of long e vaccination in solid tumors is to
identify immunogenic long peptides derived from relevant tumor associated antigens. Target
antigens should be widely expressed, and able to induce robust CD8 and CD4 anti-tumor T
cell responses. In ma, the Melan—A antigen fillfills these requirements and the
inventors recently reported the efficiency of a Melan—A modified SLP, to cross-prime human
tumor-reactive T cells (Chauvin JM et al., 2012). Another attractive target for melanoma
vaccination would be the MELOE—l antigen (46 amino , specifically overexpressed in
melanoma. Indeed, the inventors previously reported that the infusion of tumor infiltrating
lymphocytes (TIL) c for the MELOE-l antigen was associated with a prolonged
relapse-free survival for HLA-A2 melanoma patients who ed TIL therapy (Godet Y et
al., 2008). Furthermore, they nted the presence of a large and tumor reactive CD8 T
cell repertoire in HLA—A2 melanoma patients (Godet Y et al., 2010) and the presence of two
class II es in the vicinity of the class I epitope, located at the C-terminal end of the
polypeptide (Rogel A et al., 2011).
Despite these results, the identification of onal melanoma ns with a documented
immunogenic potential remains a major issue to address for melanoma immunotherapy.
SUMMARY OF THE INVENTION:
In a first aspect, the present invention provides use of a melanoma antigen peptide of less than
amino acids long comprising the amino acid sequence SEQ ID NO:5 in the manufacture of a
ment for the prevention or the treatment of ma in a t.
In a second aspect, the present invention provides use of a fusion protein comprising a melanoma
antigen peptide as defined in the first aspect and a melanoma antigen peptide comprising the amino acids
motif: - TX2NDECWPX9 (SEQ ID NO: 23) wherein X2 is e, nine, valine, isoleucine or
glutamine and X9 is alanine, valine or leucine in the manufacture of a medicament for the prevention or
the treatment of melanoma in a patient.
In a third aspect, the present invention provides use of a melanoma antigen peptide according to
the first aspect or a fusion protein according to the second aspect, wherein the patient is genotyped with
HLA-DQβ1*0201 or HLA-DQβ1*0202 s.
In a fourth aspect, the present invention provides use of a T lymphocyte that izes
ically a melanoma antigen peptide as defined in the first aspect in the manufacture of a medicament
for the prevention or the treatment of melanoma in a patient.
In a fifth , the present invention provides a method for producing said T cytes as
defined in the fourth aspect, said method comprising the steps of: (a) stimulating PBMCs or tumor
infiltrating lymphocytes obtained from a patient with at least one melanoma n peptide according to
the first aspect or a fusion protein according to the second aspect, (b) enriching the population of T
lymphocytes specific for the melanoma antigen peptide(s) used in (a), (c) optionally cloning said
population of T lymphocytes specific for the melanoma antigen peptide(s) used in (a).
In a sixth aspect, the t invention provides a melanoma antigen peptide comprising the
amino acid sequence SEQ ID NO:5, wherein said peptide has an amino acid sequence of less than 15
amino acids long, or consists of the sequence SEQ ID NO:2 or SEQ ID NO:4.
In a seventh aspect, the present invention provides a fusion protein comprising a melanoma
antigen peptide as defined in the sixth aspect and a melanoma antigen peptide comprising the amino
acids motif: - TX2NDECWPX9 (SEQ ID NO: 23) wherein X2 is leucine, nine, valine, isoleucine or
glutamine and X9 is alanine, valine or e.
AH26(12781302_1):EOR
In an eighth aspect, the t ion provides a nucleic acid sequence encoding a melanoma
antigen peptide according to the sixth aspect or a fusion protein according to the seventh aspect.
In a ninth aspect, the present invention provides an expression vector comprising a nucleic acid
sequence according to the eighth aspect.
In a tenth aspect, the t invention provides a host cell comprising an expression vector
according to the ninth aspect, n the host cell is not within a human body.
In an eleventh aspect, the present invention es antibody or fragment thereof that binds to a
melanoma antigen peptide according to the sixth aspect.
In a twelfth aspect, the present ion provides an immunising composition comprising: (a) at
least one ma antigen peptide according to the sixth aspect or (b) at least one fusion protein
according to the seventh aspect, or (c) at least one nucleic acid sequence according to the eighth aspect or
(d) at least one expression vector according to the ninth aspect, or (e) at least one host cell according to
the tenth aspect, or (f) at least one antibody according to the eleventh aspect.
In a thirteenth aspect, the present invention provides use of an antibody or fragment thereof that
binds to a melanoma antigen peptide as defined in the first aspect in the manufacture of a ment for
the prevention or the treatment of ma in a patient.
In this study, the inventors find new epitopes located all along the MELOE-1 ce and
characterized by their T helper profile of CD4 T cell response.
Thus, the invention relates to a melanoma antigen peptide comprising the amino acids sequence
selected in the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ
ID NO:5 or a function-conservative variant thereof. Moreover the invention also relates to a ma
antigen peptide according to the invention for use in the prevention or the ent of melanoma in
patient.
DETAILED DESCRIPTION OF THE INVENTION:
Definitions:
Throughout the specification, several terms are employed and are defined in the following
paragraphs.
As used herein, the term “peptide” refers to an amino acid sequence having less than 50 amino
acids. As used herein, the term de” encompasses amino acid sequences having less than 50 amino
acids, less than 40 amino acids, less than 30 amino acids, less than 25 amino acids, less than 20 amino
acids, less than 15 amino acids or less than 10 amino acids.
AH26(12387646_1):EOR
Melanoma n peptides of the invention are described in table A.
SEQ ID number Sequences Nomenclatures used in
the patent application
Peptide SEQ ID NO:1 SCVGYPDEATSREQFLPSEC MELOE21 or 2-21
Peptide SEQ ID NO:2 VGYPDEATSREQFLPS MELOE19 or 4-19
Peptide SEQ ID NO:3 VGYPDEATSREQFL 14-17 or 4-17
Peptide SEQ ID NO:4 GYPDEATSREQFLPS MELOE19 or 5-19
Peptide SEQ ID NO:5 PDEATSREQFLPS MELOE19 or 7-19
AH26(12387646_1):EOR
SmrOm
|-6 or 26-46
Peptide SEQ ID \0 7 m
|.5 or 32-45
Peptide SEQ ID \0 8 SmrOm
|_4 or 32-44
Peptide SEQ ID \'o:9 ViELOE-13144 or 31-44
Peptide SEQ ID \o:10 \/[EL0E-111_30 or 11-30
Peptide SEQ ID \'o:11 E—113_27 or 13-27
Peptide SEQ ID \‘0212 VIELOE—lpm or 14-27
Peptide SEQ ID 30:13 MELOE-115_27 or 15-27
Peptide SEQ ID 30:14 111_23 or 11-23
Peptide SEQ ID 50:15 MELOE-lim or 12-24
e SEQ ID 30:16 MELOE-lig_37 or 18-37
Peptide SEQ ID x017 MELOE-lzus or 22-46
Peptide SEQ ID 1\O:18 MELOE-124,37 or 24-37
Peptide SEQ ID \o:19 \/[ELOE-124_36 or 24-36
Peptide SEQ ID \0220 MSCVGYPDEATSREQFLPSEGAACPPW MELOE-11_46 or 1-46
HPSERISSTLNDECWPASL
e SEQ ID \O:2l GHGHSYTTAEELAGIGILTVILGVL Sa$A16—40L
Table A: melanoma antigen peptides ofthe invention
As used herein, the term "antibody" refers to a protein capable of specifically binding
an n, typically and preferably by g an epitope or antigenic determinant or said
antigen. The term ody" also includes recombinant proteins comprising the binding
domains, as well as variants and fragments of antibodies. Examples of fragments of
antibodies e Fv, Fab, Fab', F(ab')2, dst, scFv, 2, diabodies and multispeciflc
antibodies formed from antibody fragments.
"Function-conservative variants" as used herein refer to those in which a given amino
acid residue in a protein or enzyme has been changed (inserted, deleted or substituted)
without altering the overall conformation and function of the polypeptide. Such variants
e protein having amino acid alterations such as deletions, insertions and/or
substitutions. A “deletion” refers to the absence of one or more amino acids in the protein. An
“insertion” refers to the addition of one or more of amino acids in the protein. A
“substitution” refers to the replacement of one or more amino acids by another amino acid
residue in the protein. Typically, a given amino acid is replaced by an amino acid with one
having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic,
basic, hydrophobic, aromatic, and the like). Amino acids other than those indicated as
ved may differ in a protein so that the t protein or amino acid sequence similarity
between any two proteins of similar function may vary and may be, for example, from 70 %
to 99 % as determined according to an alignment scheme such as by the Cluster Method,
wherein similarity is based on the MEGALIGN algorithm. A "function—conservative varian "
also includes a polypeptide which has at least 60 % amino acid identity as determined by
BLAST or FASTA algorithms, preferably at least 75 %, more preferably at least 85%, still
preferably at least 90 %, and even more preferably at least 95%, and which has the same or
substantially r properties or fiinctions as the native or parent protein to which it is
compared. Two amino acid sequences are "substantially homologous" or "substantially
similar" when greater than 80 %, preferably greater than 85 %, preferably greater than 90 %
of the amino acids are identical, or greater than about 90 %, preferably greater than 95 %, are
similar (functionally identical) over the whole length of the shorter sequence. Preferably, the
similar or gous ces are identified by alignment using, for example, the GCG
(Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison,
Wisconsin) pileup program, or any of sequence comparison algorithms such as BLAST,
FASTA, etc.
The term “Major Histocompatibility x” (MHC) is a generic designation meant
to encompass the histo-compatibility antigen systems described in different species including
the human leucocyte ns (HLA).
The term “melanoma” as used herein includes, but is not limited to, all types of
melanocytes cancers at all stages ofprogression like metastatic melanocyte cancer.
The term “treating” a disorder or a condition refers to reversing, alleviating or
inhibiting the s of one or more symptoms of such disorder or condition. The term
nting” a disorder or condition refers to preventing one or more ms of such
disorder or ion.
As used herein, the term “patient” denotes a , such as a rodent, a feline, a
canine, and a primate. Preferably a patient according to the invention is a human.
A “therapeutically effective amount” as used herein is ed for a minimal amount
of active agent which is necessary to impart therapeutic benefit to a patient. For example, a
“therapeutically effective amount of the active agent” to a patient is an amount of the active
agent that induces, ameliorates or causes an improvement in the pathological symptoms,
disease progression, or physical conditions ated with the disease ing the patient.
The term “adjuvant” as used herein refers to a compound or a mixture that may be
non-immunogenic when administered in the host alone, but that augments the host’s immune
response to an antigen when administered conjointly with that antigen.
Peptide, fusion protein and uses thereof
A first object of the invention relates to a melanoma antigen peptide comprising the
amino acids sequence selected in the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ
ID N023, SEQ ID N024 or SEQ ID NO:5 or a fianction-conservative variant thereof.
In one embodiment, the ma n peptide has the sequence SEQ ID NO:5.
Melanoma antigen peptides of the invention, are generated from the peptide MELOE-
l (SEQ ID NO:20) as described in the patent application WC 2010 026165 and in table A.
In one embodiment, the melanoma antigen peptide of the invention is not the peptide
MELOE-l (SEQ ID NO:20).
In one embodiment of the invention, by “antigen peptide” is meant a peptide capable
ofbinding to HLA le and causing a cellular or l response in a patient.
In a preferred embodiment of the invention, said antigen peptide may comprise a
specific motif such that the polypeptide binds an HLA molecule and induces a CTL se.
In another preferred embodiment of the invention, said antigen e may se
a specific motif such that the polypeptide binds an HLA molecule and induces a helper T cell
response.
In one embodiment of the invention, said melanoma antigen peptides as described here
above are HLA-DQB1*0201 restricted.
In one embodiment of the invention, said melanoma antigen peptides as described here
above are B1*0202 restricted.
In one ment ofthe invention, said antigen peptide is an amino acid sequence of
less than 50 amino acids long that comprises the amino acid motif SEQ ID NO: 1, 2, 3, 4 or 5
as defined here above.
In another embodiment of the invention, said antigen e is an amino acid
sequence of less than 45 amino acids long that comprises the amino acid motif SEQ ID NO:
1, 2, 3, 4 or 5 as defined here above.
In another embodiment of the invention, said antigen peptide is an amino acid
ce of less than 40 amino acids long that comprises the amino acid motif SEQ ID NO:
1, 2, 3, 4 or 5 as defined here above.
In another embodiment of the invention, said antigen peptide is an amino acid
sequence of less than 30 amino acids long that comprises the amino acid motif SEQ ID NO:
1, 2, 3, 4 or 5 as defined here above.
In another ment of the invention, said antigen peptide is an amino acid
ce of less than 25 amino acids long that comprises the amino acid motif SEQ ID NO:
1, 2, 3, 4 or 5 as defined here above.
In one embodiment, the antigen peptide according to the invention comprises at least
60% identity over said SEQ ID NO: 1, 2, 3, 4 or 5 even more preferably at least 700%, at least
80%, at least 85%, at least 90%, at least 95%, at least 97% and is still able to bind to HLA
molecule and causing a cellular or humoral se in a patient.
In another embodiment, the antigen peptide according to the invention consists in the
amino acid sequence as set forth in SEQ ID NO: 1, 2, 3, 4 or 5 or a variant f comprising
at least 60%, preferably at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or
99.9% identity with SEQ ID N021 and is still able to bind to HLA molecule and causing a
cellular or humoral response in a patient.
The invention also encompasses peptides that are function-conservative variants of
antigen peptides comprising SEQ ID NO: 1, 2, 3, 4 or 5 as described here above.
Typically, the invention encompasses peptides substantially identical to antigen
es comprising SEQ ID NO: 1, 2, 3, 4 or 5 in which one or more residues have been
conservatively tuted with a functionally similar residue and which displays the
functional aspects of the n peptides comprising SEQ ID NO: 1, 2, 3, 4 or 5 as described
here above, i.e. being still able to bind to an HLA molecule in substantially the same way as a
peptide consisting ofthe given amino acid sequence.
Examples of conservative substitutions include the substitution of one non-polar
(hydrophobic) residue such as isoleucine, valine, leucine or methionine for r, the
substitution of one polar (hydrophilic) residue for r such as between arginine and
lysine, between glutamine and asparagine, between glycine and serine, the substitution of one
basic e such as lysine, arginine or histidine for another, or the substitution of one acidic
residue, such as aspartic acid or glutamic acid or r.
The term "conservative substitution" also includes the use of a chemically derivatized
residue in place of a non-derivatized residue. "Chemical derivative" refers to a t peptide
having one or more residues chemically derivatized by reaction of a functional side group.
Examples of such derivatized molecules include for example, those molecules in which free
amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups,
carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free
carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of
esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl
derivatives. The o 1e nitrogen of histidine may be derivatized to form N-im-
benzylhistidine. Chemical derivatives also include peptides which contain one or more
naturally-occurring amino acid derivatives of the twenty standard amino acids. For examples:
oxyproline may be substituted for proline; 5-hydroxylysine may be substituted for
; ylhistidine may be substituted for histidine; homoserine may be substituted for
serine; and ne may be tuted for lysine.
According to the invention, the n peptides of the invention can be obtained by
synthesizing the peptides according to the method for peptide sis known in the art.
In r embodiment, the antigen peptides of the invention may be incorporated into
polytopes or fiision proteins. Two or more peptides of the invention can be joined together
directly, or via the use of flanking sequences. Thompson et al., Proc. Natl. Acad. Sci. USA 92
(13): 5845- 5849 (1995), teaches the direct linkage of relevant epitopic ces. The use of
polytopes or fiision proteins as vaccines is well known. See, e. g. t et al., Nat.
Biotechnol. 15 (12): 1280—1284 (1997); Thomson et al. Thomson et al., J. Immunol.
, supra;
157 (2): 822- 826 (1996); Tam et al., J. Exp. Med. 171 (1) : 299-306 (1990), all ofwhich are
incorporated by reference. The Tam et a1. reference in particular shows that polytopes or
fusion proteins, when used in a mouse model, are useful in generating both antibody and
protective immunity.
Thus, the invention also relates to a filSiOI‘l protein comprising a melanoma antigen
peptide according to the invention and a melanoma antigen peptide comprising the amino
acids motif:
— TX2NDECWPX9 (SEQ ID NO: 22)
wherein X2 is leucine, methionine, valine, isoleucine or glutamine and X9 is alanine,
valine or leucine.
In one embodiment of the invention, said second melanoma antigen peptide is selected
in the group consisting ofpeptides having the sequence SEQ ID NO: 23 to SEQ ID NO: 37 as
described below.
Peptide SEQ ID NO 23
Peptide SEQ ID NO 24
Peptide SEQ ID )0 25
Peptide SEQ ID NO 26
Peptide SEQ ID \0 27
e SEQ ID \0 28
e SEQ ID \0 29
Peptide SEQ ID \0 30
Peptide SEQ ID \0 31
Peptide SEQ ID \0 32
Peptide SEQ ID \0 33
Peptide SEQ ID \0 34
Peptide SEQ ID \'O 35
Peptide SEQ ID \'O 36
Peptide SEQ ID \'O 37
In another embodiment, the melanoma antigen peptide according to the invention or
the fusion protein according to the invention may be use in the tion or the treatment of
melanoma in t.
In one embodiment, said patient is genotyped with HLA-DQB1*0201 or HLA—
DQB1*0202 alleles.
Nucleic acids, vectors, recombinant host cells and uses thereof
Another object of the invention relates to a nucleic acid sequence ng a
melanoma antigen peptide according to the invention or a fiision protein according to the
ion.
Another object of the invention relates to an sion vector comprising a nucleic
acid sequence encoding a melanoma antigen peptide according to the invention or a fitsion
protein ing to the invention.
In one embodiment of the invention, said expression vector comprises the nucleic acid
sequence corresponding to a melanoma antigen peptide having the sequence SEQ ID NO:1 to
SEQ ID NO: 5.
According to the invention, expression vectors suitable for use in the invention may
se at least one expression control element operationally linked to the c acid
ce. The expression control elements are inserted in the vector to control and regulate
the expression of the nucleic acid sequence. Examples of expression control elements include,
but are not limited to, lac system, or and promoter regions of phage lambda, yeast
promoters and promoters derived from polyoma, adenovirus, retrovirus, lentivirus or SV40.
Additional preferred or required operational elements include, but are not limited to, leader
sequence, termination codons, polyadenylation signals and any other sequences necessary or
red for the riate transcription and uent translation of the nucleic acid
sequence in the host system. It will be tood by one skilled in the art that the correct
combination of required or preferred expression control elements will depend on the host
system chosen. It will further be understood that the expression vector should n
additional elements necessary for the er and subsequent replication of the expression
vector containing the nucleic acid sequence in the host system. Examples of such elements
include, but are not d to, origins of replication and selectable markers. It will further be
understood by one skilled in the art that such vectors are easily constructed using
conventional methods or commercially ble.
Another object of the invention is a host cell comprising an expression vector as
described here above.
According to the invention, examples of host cells that may be used are eukaryote
cells, such as animal, plant, insect and yeast cells and prokaryotes cells, such as E. coli. The
means by which the vector carrying the gene may be introduced into the cells include, but are
not limited to, microinjection, electroporation, transduction, or transfection using DEAE-
dextran, lipofection, m phosphate or other procedures known to one skilled in the art.
In a red embodiment, otic expression vectors that fiinction in eukaryotic
cells are used. Examples of such vectors include, but are not limited to, Viral vectors such as
retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, us,
poliovirus; lentivirus, bacterial expression vectors, plasmids, such as pcDNA3 or the
baculovirus er vectors. Preferred eukaryotic cell lines include, but are not limited to,
COS cells, CHO cells, HeLa cells, NIH/3T3 cells, 293 cells (ATCC# CRL1573), T2 cells,
dendritic cells, or monocytes.
In one embodiment, the nucleic acid sequence according to the invention or the
expression vector according to the invention or the host cell ing to the invention may
be use in the prevention or the treatment ofmelanoma in patient.
Antibodies and uses thereof
r object of the invention relates to an dy or fragment thereof that binds to
the melanoma antigen peptide according to invention.
In one embodiment of the invention, said dy or fragment thereof binds to
melanoma antigen peptide having the sequence SEQ ID NO: 1 to SEQ ID NO: 5.
In one ment of the invention, said antibody is monoclonal. In another
embodiment ofthe invention, said antibody is polyclonal.
Such antibodies may be easily prepared, for example, according to the method
described in “Antibodies: A laboratory manual”, Lane H. D. et al. eds, Cold Spring Harbor
Laboratory Press, New York, 1989 or Antibody Engineering: Methods and Protocols, 2003,
Benny K. Lo.
MHC/peptide multimer
Another object of the invention relates to a MHC/peptide multimer comprising a
melanoma antigen peptide as bed here above. According to the invention, said
ptide multimer include, but are not limited to, a MHC/peptide dimer, , tetramer
or pentamer.
In one embodiment of the invention, said MHC/peptide multimer is a HLA-class
II/peptide multimer.
In another embodiment of the invention, said MHC/peptide multimer is a HLA-
DQB l *0201 II/melanorna n peptide multimer or a HLA—DQB1*0202/melanoma antigen
peptide multimer.
Methods for obtaining MHC/peptide ers are described in WO96/26962 and
W001/18053, which are orated by reference.
In one embodiment of the invention, said MHC/peptide er can be used to
visualise T cell populations that are specific for the complex HLA—DQB1*0201/ melanoma
antigen peptide or HLA-DQBl *0202/melanoma antigen peptide multimer as bed here
above.
In another embodiment of the invention, said MHC/peptide multimer can be used for
the detection and/or isolation by screening (in flow cytometry or by immunomagnetic
screening) of T cell population that are specific for a complex HLA/ melanoma antigen
peptide as described here above.
In another embodiment of the invention, said HLA-DQBl*0201/ melanoma antigen
peptide or Bl*0202/melanoma antigen peptide er can be used for the
detection and/or isolation by screening (in flow cytometry or by magnetic screening)
of T cell population that are specific for a complex HLA-DQBl*0201/ ma antigen
peptide or HLA—DQBl *0202/melanoma antigen peptide multimer as described here above.
Another object of the invention is beads coated with MHC/peptide multimers as
described here above.
Immunizing composition and uses thereof
Another object of the invention relates to an immunising composition comprising:
(a) at least one melanoma antigen peptide as described here above or
(b) at least one fusion protein as bed here above, or
(c) at least one nucleic acid sequence as described here above, or
(d) at least one expression vector as described here above, or
(e) at least one host cell as described here above, or
(t) at least one antibody as bed here above.
In one ment, said immunising composition comprises a melanoma antigen
peptide having a ce SEQ ID NO: 1 to SEQ ID NO: 5.
The lactic administration of the immunizing composition of the invention
should serve to t or attenuate melanoma in a mammal. In a preferred embodiment
mammals, preferably human, at high risk for melanoma are prophylactically treated with the
immunising composition of the invention. Examples of such mammals e, but are not
limited to, humans with a family history ofmelanoma.
When provided eutically, the immunising composition of the invention is
provided to enhance the patient's own immune se to the melanoma antigen present on
the melanoma or metastatic melanoma.
In one embodiment of the invention, the peptides of the invention may be conjugated
with lipoprotein or administered in liposomal form or with adjuvant.
In one embodiment, said immunising composition is a pharmaceutical composition.
In such embodiment, said immunising composition, for human use, comprises at least
one n peptide as described here above or at least one antibody as described here above,
together with one or more pharmaceutically acceptable carriers and, optionally, other
therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible
with the other ingredients of the composition and not deleterious to the recipient thereof. The
immunising compositions may conveniently be presented in unit dosage form and may be
prepared by any method well-known in the ceutical art.
Immunising compositions suitable for intravenous, intradermal, intramuscular,
subcutaneous, or intraperitoneal administration conveniently comprise sterile aqueous
ons of the active agent with solutions which are preferably isotonic with the blood of the
recipient. Such itions may be conveniently prepared by dissolving solid active
ient in water containing physiologically compatible substances such as sodium chloride
(eg. 0.1-2.0M), glycine, and the like, and having a buffered pH compatible with physiological
conditions to produce an aqueous solution, and rendering said solution sterile. These may be
present in unit or multi—dose containers, for example, sealed ampoules or Vials.
The immunising compositions of the invention may incorporate a stabilizer.
rative stabilizers are polyethylene glycol, proteins, saccharides, amino acids, inorganic
acids, and organic acids which may be used either on their own or as ures. These
stabilizers are preferably incorporated in an amount of 0.11-10,000 parts by weight per part
by weight of active agent. If two or more stabilizers are to be used, their total amount is
preferably within the range specified above. These stabilizers are used in aqueous solutions at
the appropriate concentration and pH. The specific osmotic pressure of such aqueous
ons is generally in the range of 0.1-3.0 osmoles, preferably in the range of 0.8-1.2. The
pH ofthe aqueous solution is adjusted to be within the range of 5.0—9.0, preferably within the
range of 6-8.
Additional pharmaceutical methods may be employed to control the duration of action.
Controlled release preparations may be achieved through the use of polymer to complex or
absorb the peptides of the invention. The controlled ry may be exercised by selecting
appropriate macromolecules (for example polyester, polyamirio acids, polyvinyl, pyrrolidone,
ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the
concentration of macromolecules as well as the methods of incorporation in order to control
release. Another possible method to control the duration of action by controlled-release
preparations is to incorporate the antigen peptides of the invention into particles of a
polymeric material such as polyesters, ino acids, hydrogels, poly(lactic acid) or
ethylene ceiate copolymers. Alternatively, instead of incorporating these agents into
polymeric particles, it is possible to entrap these als in microcapsules ed, for
example, by coacervation techniques or by interfacial polymerization, for example, hydroxy—
methylcellulose or gelatin-microcapsules and poly(methylmethacylate) microcapsules,
respectively, or in colloidal drug delivery systems, for example, mes, n
pheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions.
When oral preparations are desired, the itions may be combined with typical
carriers, such as lactose, sucrose, starch, talc magnesium stearate, crystalline cellulose, methyl
ose, ymethyl cellulose, glycerin, sodium alginate or gum arabic among others.
Immunisation of a t with the immunising composition of the invention can be
conducted by conventional s, for example, in the presence of tional adjuvants.
Examples of conventional adjuvant include, but are not limited to, metal salts, oil in water
emulsions, Toll like receptors agonists, ns, lipid A, alkyl glucosaminide phosphate,
Freund's adjuvant, keyhole limpet haemocyanin (KLH), mannan, BCG, alum, cytokines such
as IL—1, IL—2, macrophage colony stimulating factor, and tumor necrosis ; and other
substances that act as stimulating agents such as muramyl peptides or bacterial cell
wall components, toxins, toxoids and TLR ligands.
The immunising composition can be administered by any route appropriate for
antibody production and/or T cell activation such as intravenous, intraperitoneal,
intramuscular, aneous, and the like. The immunising composition may be stered
once or at periodic intervals until a significant titre of anti-Nectin4 immune cells or anti-
4 antibody is produced. The presence of anti-Nectin4 immune cells may be assessed by
measuring the frequency of precursor CTL ic T-lymphocytes) against the antigen
peptides of the invention prior to and after immunization by specific tetramer labelling or by a
CTL precursor analysis assay. The antibody may be detected in the serum using an
immunoassay.
Antibodies ed to the antigens of the invention can also be used directly as anti-
melanoma agents. To prepare antibodies, a host animal may be zed using melanoma
antigen e as described here above. The host serum or plasma is collected following an
riate time to provide a composition comprising antibodies reactive to said n
peptides. The gamma globulin fraction or the IgG antibodies can be ed, for example, by
use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those
skilled in the art. The antibodies are substantially free of many of the adverse side effects
which may be associated with other anti-cancer agents such as chemotherapy.
The immunising composition ofthe invention comprising antibodies as described here
above can be made even more compatible with the host system by minimizing potential
adverse immune system responses. This is accomplished by removing all or a portion of the
Fc portion of a foreign species antibody or using an dy of the same species as the host
patient, for example, the use of antibodies from human/human hybridomas. Humanized
antibodies (i.e., nonimmunogenic in a human) may be produced, for e, by replacing an
immunogenic portion of an antibody with a ponding, but nonimmunogenic portion (i.e.,
chimeric antibodies). Such chimeric antibodies may contain the reactive or antigen binding
portion of an antibody from one species and the Fc portion of an antibody munogenic)
from a ent species. Examples of chimeric antibodies, include but are not limited to,
an mammal-human chimeras, rodent—human chimeras, murine—human and rat-human
chimeras.
Methods for obtaining said antibodies, chimeric antibodies and humanized chimeric
antibodies are well—known in the art.
The immunising composition comprising the antibodies of the invention can also be
used as a means of enhancing the immune response. The antibodies can be administered in
amounts similar to those used for other therapeutic administrations of antibody. For example,
pooled gamma globulin is administered at a range of about 1mg to about 100mg per patient.
Thus, antibodies reactive with the antigen peptides of the invention can be passively
administered alone or in conjunction with other anti-cancer therapies to a mammal afflicted
with cancer. Examples of anti-cancer therapies include, but are not limited to, chemotherapy,
radiation therapy, adoptive immunotherapy therapy with TIL.
The antibodies or chimeric antibodies described herein may also be coupled to toxin
molecules, sotopes and drugs by conventional methods. Examples oftoxins to which the
antibodies may be coupled to included, but are not limited to, ricin or diphtheria toxin.
es of drugs or chemotherapeutic agents include, but are not limited to,
cyclophosphamide or doxorubicin. Examples of radioisotopes, include, but are not limited to,
1311. Antibodies covalently conjugated to the aforementioned agents can be used in cancer
immunotherapy for treating melanoma.
If the patient to be immunized is already afflicted with cancer or metastatic cancer, the
immunising composition of the invention can be administered in ction with other
therapeutic treatments. Examples of other therapeutic treatments includes, but are not limited
to, adoptive T cell therapy, coadministration of cytokines or other therapeutic drugs
for cancer.
The dose of antigen peptide of the invention to be administered to a patient may be
adjusted as appropriate depending on, for example, the disease to be treated, the age and the
body weight of said patient. Ranges of n peptides of the invention that may be
administered are about 0.001 to about 100 mg per t, preferred doses are about 0.01 to
about 10mg per patient.
The immunising composition of the invention may be ted first in animal
models, lly rodents, and in an primates and finally in humans. The safety of the
immunization procedures is determined by looking for the effect of immunization on the
general health of the immunized animal (weight change, fever, appetite behavior etc.) and
looking for pathological changes on autopsies. After initial testing in animals, cancer patients
can be tested. Conventional s would be used to te the immune se of the
patient to ine the efficiency of the immunising composition.
Another object of the invention s to an immunising composition as described
above for use in the prevention or treatment of melanoma in a patient in need thereof.
In another embodiment, said patient is genotyped with HLA-DQB1*0201 or HLA-
DQ[31*0202 alleles.
Antigen presenting cell
Another object of the invention is an antigen presenting cell sing a complex
HLA n and a melanoma antigen peptide ofthe invention.
In one embodiment of the invention, said x HLA antigen is a HLA-
DQBI*0201 or HLA-DQBI *0202 antigen.
In one embodiment of the invention, said antigen presenting cell is derived from the
patient to be d.
The term "antigen presenting cell" (APCs) refers to any cell that expresses an HLA
antigen capable of presenting the n peptide of the invention on its surface. Dendritic
cells, which are reported to have an especially high antigen-presenting ability, are preferred.
In another embodiment, artificial APCs may also be used such ian cells (fibroblast,
endothelial cells, keratinocytes), or cell lines.
In order to prepare such APCs of the invention, cells having an antigen-presenting
ability are isolated from the patient to be treated, and pulsed ex vivo with at least one antigen
e of the ion to form a complex with the HLA-DQB1*0201 or HLA-DQB1*0202
antigen.
In case dendritic cells are used, the APC of the invention can be prepared as follows.
Lymphocytes are isolated from peripheral blood of the patient to be treated by Ficoll method;
adherent cells are separated from non-adherent cells; the adherent cells are then cultured in
the presence of GM-CSF and IL-4 to induce dendritic cells; and the dendritic cells are pulsed
by culturing with at least one antigen peptide of the invention to obtain the APCs of the
invention. The dendritic cells should be exposed to the antigen peptide for sufficient time to
allow the antigens to be alized and presented on the dendritic cells surface. The
resulting dendritic cells can then be re-administrated to the patient to be treated. Such
s are described in WO93/208185 and EP0563485, which are incorporated by
reference.
Another object of the invention is a composition for active immunotherapy comprising
n presenting cells comprising a complex HLA n and a melanoma antigen peptide
ofthe invention.
In one embodiment of the ion, said antigen presenting cells comprise a complex
HLA-DQBI *0201 or HLA—DQB1*0202 antigen and a melanoma antigen peptide of the
invention.
Said APCs may be preferably ned in physiological saline, phosphate buffered
saline (PBS), culture medium, or the like. Administration may be achieved, for example,
intravenously, hypodermically, or intradermally.
Lymphocytes T and uses thereof
Another object of the invention relates to a T lymphocyte that recognizes specifically
the melanoma antigen e ofthe invention or a fusion protein of the invention.
In one embodiment of the invention, said T lymphocyte is a T lymphocyte helper.
In another ment of the invention, said T lymphocyte is HLA-DQB1*0201 or
HLA-DQBl *0202 restricted.
In another embodiment of the invention, said T lymphocyte is a T cell Clone.
In another embodiment, said T lymphocyte is a genetically modified T cyte
that expresses a TCR that recognizes specifically the melanoma antigen peptide of the
invention.
r object of the invention is a composition for adoptive therapy sing said
T lymphocytes as described here above that recognizes specifically the melanoma antigen
peptide of the invention or a filSlOIl protein of the invention.
In the case of melanoma, it has been observed that an adoptive immunotherapy
wherein intratumoral T cell infiltrate taken from the patient to be treated are cultured ex vivo
in large quantities, and then ed into the patient achieves a therapeutic gain.
It is preferred that the T cells are contained in physiological saline, phosphate ed
saline (PBS), culture medium, or the like in order to their stable maintain. Administration may
be achieved, for example, intravenously or tumoraly. By returning the T cells that
recognizes specifically the antigen peptide of the invention into the patient’s body, the
toxicity of said T cells, or the stimulation of CD8 xic T cells by said cells towards
tumor cells is enhanced in the patient who is positive for the melanoma n peptide of the
invention. The tumor cells are yed and thereby the treatment oftumor is achieved.
Examples of where T-lymphocytes can be ed, include but are not limited to,
peripheral blood cells lymphocytes (PBL), lymph nodes, or tumor infiltrating lymphocytes
(TIL).
Such lymphocytes can be isolated from tumor or peripheral blood of the individual to
be d by methods known in the art and cultured in Vitro. Lymphocytes are cultured in
media such as RPMI or RPMI 1640 for 2—5 weeks, preferably for 2—3 weeks. Viability is
assessed by trypan blue dye exclusion assay. The cytes are exposed to the antigen
peptide of the invention for all of the culture duration.
In a red embodiment the lymphocytes are exposed to the melanoma antigen
peptide of the ion at a concentration of about 1 to about 10 micrograms(ug)/ml for all
the on of lymphocyte culture. Cytokines may be added to the lymphocyte culture such
as IL-2.
The melanoma antigen peptide of the invention may be added to the culture in
presence of antigen presenting cells such as dendritic cells or allogeneic ated cancer cell
line cells.
After being sensitized to the peptide, the T—lyrnphocytes are administered to the
patient in need of such treatment.
Examples of how these sensitized T-cells can be administered to the mammal include
but are not limited to, intravenously, intraperitoneally or intralesionally. Parameters that may
be assessed to ine the efficacy of these ized T-lymphocytes include, but are not
limited to, production of immune cells in the patient being treated or tumor regression.
Conventional methods are used to assess these parameters. Such treatment can be given in
conjunction with cytokines or gene modified cells (Rosenberg, S.A. et a1. (1992) Human
Gene Therapy, 3: 75-90; Rosenberg, SA. et a1. (1992) Human Gene Therapy, 3: 57-73).
Another object of the invention is a method for producing T cytes that
recognize specifically a melanoma n peptide of the invention, said method comprising
the steps of:
(a) stimulating peripheral blood mononuclear cells (PBMCs) or tumor infiltrating
lymphocytes (TIL) obtained from a patient with at least one melanoma antigen peptide of the
invention or a fusion protein of the invention,
(b) ing the population of T lymphocytes specific for the melanoma antigen
peptide(s) used in (a),
(c) optionally cloning said population of T lymphocytes specific for the melanoma
antigen peptide(s) used in (a).
Enrichment and/or cloning may be carried out by using an MHC/peptide multimer as
described here above. g may also be carried out by conventional s.
In one embodiment of the invention, the T lymphocytes that recognize specifically a
melanoma antigen peptide of the invention are HLA—DQB1*0201 or HLA-DQBI*0202
restricted. In such embodiment, enrichment and/or cloning may be carried out by using an
HLA-DQ[31*0201 or HLA-DQ[31*0202 /peptide multimer as described here above.
Stimulation ofPBMCs may be carried out with at least one melanoma antigen peptide
of the invention alone, or presented by an antigen presenting cell such as dendritic cells or
allogeneic irradiated cancer cell line cells. Typically, cytokines such as IL-2 may also be
added to the culture.
Another object of the invention is a composition for adoptive y that comprises
lymphocytes that recognizes specifically the melanoma antigen peptide of the invention for
preventing or treating melanoma in a patient in need f, wherein said T lymphocytes are
to be re-administrated to the patient.
In one embodiment, said lymphocytes that recognizes specifically the antigen peptide
ofthe invention are HLA-DQB1*0201 or HLA-DQ[31*0202 restricted.
The invention also relates to a method for preventing or treating ma in a patient
in need thereof, comprising administering a therapeutically effective amount of
(a) at least one melanoma antigen peptide as described here above or
(b) at least one fusion n as described here above, or
(c) at least one nucleic acid sequence as described here above, or
(d) at least one expression vector as bed here above, or
(e) at least one host cell as described here above, or
(f) at least one antibody as described here above.
The invention also relates to a method for preventing or treating melanoma in a patient
in need f, comprising administering a therapeutically ive amount of T
lymphocytes that recognizes specifically the ma antigen peptide of the invention. In
one ment, said T lymphocytes are Bl *0201 or HLA-DQB1*0202 restricted.
The invention also relates to a method for preventing or treating melanoma in a patient
in need f, comprising administering a therapeutically effective amount of antigen
presenting cells sing a complex HLA antigen and a ma antigen peptide of the
invention. In one embodiment, said complex HLA/peptide is a complex HLA-DQB1*0201 or
HLA-DQB1*0202 / antigen peptide of the invention.
The invention will be further rated by the following figures and examples.
However, these examples and figures should not be interpreted in any way as ng the
scope of the present invention.
FIGURES:
Figure 1: (A) Percentages of TNF-Ot producing CD4 T cells among positive
ultures. Fourteen days after PBMC stimulation with MELOE-l whole polypeptide (2-
46), microcultures were re—stimulated with each indicated peptide during 5 hours. TNF-Ot
production was then assessed by a double labeling TNF-Ot -CD4. Results were analyzed with
a non—parametric test (Kruskal—Wallis) followed by a Dunns post—test. (B) Frequency of
microcultures containing CD4 T cells specific for MELOE-l peptides (assessed by TNF-(l
intracellular staining after re-stimulation with the 4 indicated peptides). 624 microcultures
(from 7 healthy donors) were analyzed by a contingency table ed by a Fisher exact test.
Figure 2: (A) tages of cytokine producing CD4 T cells among positive
microcultures. Fourteen days after PBMC stimulation with MELOE-l whole polypeptide (2-
46), microcultures were re-stimulated with each indicated peptide during 5 hours. IFN—y (left
panel) and IL4 (right panel) production was then assessed by a triple ng IFN—y -IL4-
CD4. Results were analyzed with a non-parametric test (Kruskal-Wallis) followed by a Dunns
post-test. (B) Frequency of microcultures ning CD4 T cells specific for l
peptides (assessed by IFN—y or 1L4 intracellular staining after re-stimulation with the 3
indicated peptides). 576 microcultures (from 10 melanoma patients) were analyzed by a
contingency table followed by a Fisher exact test.
Figure 3: HLA-restricting element of MELOE-l c T cell clones and reactivity
against HLA-matched melanoma cell lines. The HLA restriction of MELOE—l specific T cell
clones was first assessed using anti-HLA blocking antibodies (upper panel). T cell clones
were stimulated for 5 hours in the presence of din A (10 ug/mL) either with peptide
alone (10 uM) in an autopresentation assay and in presence or not of blocking antibodies at a
concentration of 12.5 ug/rnL. HLA restriction was confirmed with HLA-matched B—EBV cell
lines pulsed 2 hrs with the cognate peptide, at a ratio 1: 2 (middle panel). Reactivity of each T
cell clone against HLA-class II expressing melanoma cells was assessed, in presence or not of
exogeneous peptide (lower panel). After 5 hours of stimulation, cells were then stained with
njugated anti-CD4 mAb, fixed with 4% paraformaldehyde, labeled with PE-
conjugated anti—TNF—or mAb and analyzed by flow cytometry.
Figure 4: Class II epitopes are naturally processed from MELOE-l whole antigen.
gous DC, were loaded (before or after fixation) with MELOE-12_46 (1 uM) or, as a
ve control, with AlMOL peptide (1 uM), and matured. T cell clones were then
stimulated with DC at a ratio 1: 1, during 5h in presence of Brefeldin A, then stained with
APC-conjugated anti-CD3 mAb, fixed with 4% paraformaldehyde, labeled with PE-
conjugated anti-TNF-or mAb and analyzed by flow cytometry. Histograms illustrated the % of
TNF-OL producing cells among CD3 positive T cells.
Figure 5: l peptides recognized by MELOE—l specific CD4 T cell clones.
MELOE-l specific CD4 T cell clones were incubated with various concentrations of the
indicated es during 5 hours in presence of Brefeldin A. TNF-OL production was ed
by intracellular labeling with an anti-TNF-(x specific antibody. The core peptide sequence is
indicated in bold on each figure panel, and black circles rate the best fitting peptide.
MELOE-l MSCVGYPDEATSREQFLPSEGAACPPWHPSERISSTLNDECWPASL
MELOE-12.21 SCVGYPDEATSREQFLPSEG l
MELOE-111_30 TSREQFLPSEGAACPPWHPS 10
118_37 PSEGAACPPWHPSERISSTL 16
MELOE'126-46 PWHPSERISSTLNDECWPASL 6
MELOE-122.45 AACPPWHPSERISSTLNDECWPA SL 17
Table I: MELOE—l and l derived peptide sequences.
All the peptides were sed from Millegen y (France), with a purity >
85%. In bold are indicated the DR—ll (SEQ ID N018) and the DQ—6 (SEQ ID NO:8)
overlapping epitopes already described, and in italics is indicated the HLA-A2 restricted class
I epitope (TLNDECWPA, SEQ ID NO:23)).
ultures containing MELOE-l specific CD4+ T cells
TNF-(x roduction
MELOE-111_ MELOE-118_ 126_
MELOE-IMI Class II HLA
37 46
DPB 1 *0902/1501
9/96 13/96 6/96 5/96
DQBl*0301
(1.4%::O.6) (2.4%115) (1.4%i0.6) (1.5%:05)
DRBl*1104/1201
DPBl*0401/0301
6/96 26/96 7/96 10/96
HD” DQBl*0301/0603
(3.2%:19) (8.2%i6.5) (30/0107) (5.2%:41)
DRBl*1101/1301
ngglfioligéém* 1/96 2/96 2/96
HD22 0/96
(1%) (3.9%:t3.3) (1%i0-1)
DRBl*0701
DPBl*0401/0101
HD24 0/96 0/96 DQBI*0501/0602
(1 33:60 8). 0 . 0:619?”0 ~ DRBI*0101/1501
mm 0/96
(0 63/9160.
nggBolglz/gioz
o . 1) (1 23/9160 7). o . (1 ' 11/5260 9)
° - 0301
DPBl NA
/96
HD27 0/96 0/96 0/96 DQBI*501/0201
(50/ i 3 4)o - DRBl*0101/0301
DPBI NA
/48 14/48 0/48
Hms 0/96 DQNA
Table 11: Assessment of MELOE—l CD4 T cell responses in PBMC from y
donors.
PBMC from healthy donors were stimulated with 10 uM of MELOE-l. Afier 14 days,
the ce of CD4 T cells specific for the different regions of l was assessed by
restimulating cells with 12_21, MELOE-111_30, MELOE—118_37 and 125_46
peptides, followed by CD4 / TNF—(x double staining and flow cytometry analysis. Between
brackets is indicated the mean % of TNF—oc producing CD4 T cells, in positive microcultures.
NA : not available.
Microcultures containin_ MELOE-l s l ecific CD4+ T cells
Th2 responses (1L4 positive
m1crocultures) mlcrocultures)
-MELOE- MELOE- MELOE—ln MELOE- MELOE- MELOE-
12-21 111-30 46 12-21 111-30 122-46
1/48 10/48 11/48 1/48 4/48
0/48
(0.7%) (1.4%407) (4.8%i72) (1%) (0.8%::0.3)
4/96 16/96 2/96
”6 0/96 0/96
.2) (1.6%i1.2) (0.6%::0.02)
Pt¢3
DPBl*0201/
2001 5/96
4/96
DQ1315001303/* (16.24133.0 0/96 0/96
- - (1.9%i1.3)
DRBl*0101/
9/48 1/48
(”48 0/48 0/48
(0.9%405) (07%)
1/48 6/48 2/48 1/48
(0.6%) 1.1)-(0.7%40.1> “8
(0.8%)
/48
0/48 0/48 0/48 0/48 0/48
(1.5%2‘21-9)
28/48 7/48
(2.9%43.5)(1.5%4=0.7>
2/48
1/48 1/48
9/48 3/48
l/48
Ptyé9 0/48 0/48 0/48
0 (0.6%i0.09 (0.7%:t0,15
) )
Table III: Assessment of MELOE-l CD4 T cell responses in PBMC from melanoma
patients.
PBMC from melanoma patients were stimulated with 10 MM of MELOE—l. After 14
days, the presence of CD4 T cells specific for the different regions of MELOE-l was assessed
by restimulating cells with MELOE-12_21, MELOE-111_30 iVI-E-LQE—l-w and MELOE-122_46
peptides, followed by CD4/IFN—y double staining for the detection of Th1 responses, and by
CD4/1L4 double staining for Th2 responses. n brackets is indicated the mean % of
cytokine producing CD4 T cells, in ve microcultures.
MELOE21 Specific CD4 T cell clone (9C12-
DQBI*0202)
TNF 1g
GM-CSF 1g
1L4 'g
MELOE-111_30 s.ecific CD4 T cell clone I51 *0101
V beta chain a% "g
CDR3 beta IFN ‘
J beta chain 1L2 °W
GM-CSF 03
1L4 03
l—tl—t hr5‘”negH(IO
ILlO neg
MELOE-125_46 specific CD4 T cell clone (4E2-
DQB 1 *0201)
TNF "g
GM-CSF 1g
D—l|—( rr‘m4}- _%oa(to
IL13
ILlO neg
Table IV: TCR characterization and cytokine profile of MELOE-l specific CD4 T cell clones
CD4 T cell clones were stimulated for 5 hours in the presence of brefeldin A (10 ug/mL) either with
the cognate peptide (10 uM) in an autopresentation assay. After 5 hours of stimulation, cells were
stained with AFC-conjugated D4 mAb, fixed with 4% paraformaldehyde, labeled with PE-
conjugated anti-cytokine mAb and analyzed by flow cytometry.
Material & Methods
Cells
Blood samples from healthy subjects and melanoma patients were respectively
obtained from ssement is du Sang, Nantes, France and from the department of
onco-dermatology, Nantes Hospital, France. Melanoma and B-EBV cell-lines were
maintained in RPMI 1640 ) containing 10% fetal calf serum (FCS). cytes
were grown in RPMI 1640 8% human serum (HS) with 50 or 75 IU/ml of recombinant
interleukin-2 (IL-2, Chiron, France) and 2nM of L—Glutamin. For experiments using dendritic
cells (DC), RPMI supplemented with 20mg/mL of human albumin (LFB
BIOMEDICAMENTS, France) was used to avoid peptide degradation by serum proteases.
Reagents
Antibodies were purchased fiom BD Biosciences-France or from Miltenyi Biotec,
France. Purified cytokines were purchased from CellGeniX, Germany. The different peptides
(Millegen, France, purity >85%) used in this study are described in Table I. HLA-
A*0201/MELOE-136,44 rs were generated by the recombinant protein facility of our
institute (SFR 26).
Dendritic cells tion and loading
Monocytes were purified from PBMC of healthy donors by a CD14-enrichment kit,
according the recommendations of the supplier (Stem Cell, France). Immature dendritic cells
(iDC) were generated by culturing monocytes in RPMI supplemented with 20mg/mL of
human albumin, 1000 IU/mL of GM-CSF and 200 IU/mL of 1L-4 for 5 days. Then, iDC were
pulsed with the whole MELOE-l (luM) n or the ed Melan—A16_40 A27L as
ve control (1 uM) and matured with 20 ng/mL ofTNF-0t and 50 ug/mL of PolyI:C for 4
hours at 37°C. Finally they were fixed for 1 minute with PBS/0.015% glutaraldehyde.
atively, iDC were first matured, fixed and then pulsed with antigens at the same
concentration.
Stimulation ofMELOE-l specific T cells
PBMC from healthy donors or melanoma patients (2.105 cells/well) were cultured for
14 days with 10 uM of MELOE-l whole antigen (46 amino acids) in RPMI medium
supplemented with 8% HS, 50 IU/ml of rIL-2 (Chiron, France) and L-Glutamin, in 96—well
multiplates. Microcultures were then restimulated individually with each pping peptide
(MELOE-12_21, MELO E—111_3o, MELOE-l 1837, MELOE-126_46 or MELOE-122_45 for
melanoma patients) in the presence of 10 ug/mL brefeldin A for 5 hours and the percentage of
CD4+ specific T cells was assessed by TNF-0t, IFN—y or 1L-4 intracellular staining. A negative
control without e was included in all experiments.
Alternatively, MELOE-l specific CD4+ T cell clones were stimulated by autologous
MELOE-l loaded and matured DC at a 1:1 ratio.
T cell cloning and TCR characterization
Polyclonal cultures containing specific CD4+ T cells were cloned by limiting dilution
as previously bed (Gervois N. et al., 2000). After 2 weeks, each clone was checked for
peptide specificity by TNF production assay. For TCR sequencing, RNA from 5.106 T cell
clones was extracted with RNable reagent (Eurobio, ) according to the supplier's
ctions. Reverse transcriptions, PCR cations and cing were performed as
described (Davodeau F. et a1, 2001). We used the TCR nomenclature established by Arden et
al. (Arden et al., 1995);
TNF production assay
CD4+ T cell clones were cultured for 5 hours at 37°C in the presence of the recognized
-mer peptide. e supernatants were harvested and TNF was measured in a biological
assay using cytotoxicity against WEHI 164 clone 13 (Espevik T. et al., 1986).
Cfiokine intracellular staining
Lymphocytes were stimulated for 5 hours in the presence of brefeldin A (10 ug/mL)
either with peptide alone (10 uM) in an autopresentation assay or with B—EBV or HLA-class
II expressing melanoma cells pulsed 2 hours with the cognate peptide, at a ratio 1: 2. In some
ments, blocking mAb against HLA-DP (clone B7.21 from Dr n, UMR940,
Paris), HLA—DQ (clone SPVL3, Beckman Coulter) or HLA—DR (clone L243, BD
Biosciences) were added at a concentration of 12,5 ng/ml. Cells were then stained with APC-
conjugated anti-CD4 mAb, fixed with 4% paraformaldehyde, labeled with PE-conjugated
anti-cytokine mAb and analyzed by flow cytometry.
Statistical analyses
Statistical analyses were done with GraphPad Prism® software. Bar graphs were used
to compare ncies of T cells specific for MELOE-l—derived es, in all donors and
patients and were analyzed by a contingency table followed by 21 Fisher exact test. Scatter-dot
graphs were made to compare the percentage of TNFOL positive cells among positive
microcultures and were analyzed with a non-parametric test (Kruskal—Wallis followed by a
Dunns post-test).
Frequency and distribution of MELOE-l specific CD4 responses in healthy donor’s
PBMC stimulated with l n
Our purpose was to look for the nce of class II helper epitopes all along
MELOE-l sequence (SEQ ID NO: 20), in order to document the immunogenicity of the
different regions of this melanoma antigen. We stimulated 2.107 PBMC from seven healthy
donors with MELOE-l whole n and tested, after a 14-day culture period the presence of
CD4 T cells specific for each region of the protein. Microcultures were screened for TNFOL
production by CD4+ T cells, after restimulation with four MELOE-l derived overlapping
peptides (Table I), in an autopresentation assay. As shown in table II, all donors exhibited
CD4 responses against at least 1 out of 4 overlapping peptides. ses against the N-
terminal region of MELOE-l (2-21) were detected in 6/7 donors, with rather low frequencies
(from 1 to 9% of positive microcultures containing between 0.6 to 5.6% of TNFOL producing
CD4 T cells), unless in HD28 healthy donor, who exhibited 62% of positive microcultures.
The region 11-30 appears ally immunogenic, with CD4 specific responses detected in
each tested donor (from 2 to 48% of positive microcultures containing between 0.7 to 24 % of
TNFO. producing CD4 T cells), and with very high frequencies in three donors (HDl7, HD24
and HD28). On the contrary, the central region 18—37, containing an already described DRl l-
restricted epitope (24-37) located just at the end of this 20-mer peptide (Rogel et al., 2011),
induced specific responses in microcultures deriving from only 2/7 donors (HD9 and HD17,
both expressing the DRII element). In these two donors, we detected 6 and 7% of positive
microcultures, containing between 0.6 to 3.7 % of TNFoc producing CD4 T cells. Finally, the
C-terminal region (26-46), containing an already described DQ6-restricted epitope (Rogel et
al., 2011), was recognized by ated microcultures from 4 out of 7 donors (all do not
expressing the DQ6 element), with frequencies ranging from 2 to 16% of microcultures
containing between 0.5 and 16% of TNFOt producing CD4 T cells. Overall, the frequency of
MELOE-111_3o ve microcultures was significantly higher than frequency of
ultures specific for the three other regions of MELOE-l (Figure 1B) (p<0.0001). The
two terminal regions (2-21 and 26-46) were equivalent in terms of frequencies of positive
microcultures, and these two regions induced significantly more responses than the central
region 18-37 (Figure 1A). Nonetheless, the mean fractions of CD4 reactive T cells induced in
positive microcultures were not significantly ent from a region to another (Figure 1B).
Frequency, distribution and Th profile of MELOE-l specific CD4 responses in
melanoma patient’s PBMC stimulated with MELOE-l antigen
In order to confirm the immunogenicity of each MELOE-l s in melanoma
patients, we stimulated melanoma ts PBMC with the MELOE-l whole protein, and
tested the reactivity of ated lymphocytes towards the three most immunogenic regions:
2-21, 11-30, and 22-46. For this study, instead of challenging microcultures with the 18-37
e, that appeared poorly immunogenic, we extended the C—terminus region from 26-46 to
22—46, in order to also detect ses to our previously described HLA—DRll—restricted
epitope (24-37). Indeed, the location of this epitope just at the end of the 18-37 e could
be deleterious for the detection of c responses in onal DR contexts, and we
previously showed that CD4 T cells c for MELOE-lz4_36 epitope were efficiently
induced by 22-46 peptide stimulation (Rogel et al., 2011). We tested the ion of CD4
specific responses from MELOE-l stimulated PBMC of 10 melanoma patients. We
documented CD4 responses c for the central region of MELOE-l (11-30) for 7/9
patients, whereas responses specific for MELOE-12_21 and MELOE-122_46 were respectively
detected in 4/9 and 5/9 patients (Table 111). These responses were mainly Thl responses (IFN—
g production) while less frequent Th2 responses c for the three regions of MELOE-l
were detected in 3/9 patients for 12_21, 2/9 patients for MELOE-111_30 and 5/9
patients for 122_46 (Table III). Considering the various regions of MELOE-l, Thl
responses specific for the N—term region of MELOE-l (2-21) were significantly less frequent
than those specific for the central region (p<0.0001) and the C-term region 001), with
respectively 3.3%, 10.8% and 9.6% of 576 tested microculutures (Figure 2A). Concerning
Th2 responses, much less frequent, the C-term region appeared to induce more frequently the
growth of lL-4 producing CD4 T cells than the two other regions (Figure 2A). As observed
for healthy donors, even if the frequencies were different, the mean fiaction of reactive T cells
(Thl and Th2) induced in positive microcultures were not significantly ent from a
region to another (Figure 2B). In summary, stimulation of patient’s PBMC with MELOE-l
induced Thl responses specific for diverse epitopes located all along the protein sequence,
and among the different regions, the central region (1 1—3 0) and the C-term region (22-46)
appeared to be especially genic in term of frequency of responses.
Production and characterization of CD4 T cell clones specific for the different regions
In order to ly characterize the recognized epitopes, we derived CD4 T cell
clones specific for each region of MELOE—l by ng dilution, from microcultures of
healthy donors or melanoma patients, ning at least 0.5% of specific CD4 T cells. We
succeeded to derive CD4 specific T cell clones from HD17, HD22, HD25 and Pt¢3
microcultures, which were reactive against MELOE-12_21 (HD22), MELOE-111_30 (HDl7 and
Pt¢3) and MELOE-lg6_46 (HD25). From each g experiment, we obtained between one
and ten reactive CD4 T cell clones, that turned out to be the same clonotype after CDR3B
sequencing (Table IV). A single CD4 T cell clone for each specificity was used for further
experiments. The HLA-restriction was determined for each T cell clone, first by using HLA-
class II blocking monoclonal antibodies (Figure 3, upper panel), and further by testing the
recognition of HLA—matched B—EBV cell lines loaded with each recognized long e
(Figure 3 middle panel). The two T cell clones named 9Cl2 and 4E2, derived from HD22 and
HD25 and specific for MELOE-12_21 and MELOE—12646 were restricted by the HLA-
DQBl*0202 and the 201 molecules respectively. As, these two donors were
homozygous for the HLA—DQ locus, a single HLA-DQ matched B—EBV cell line was tested
to confirm the HLA restriction of these two CD4 T cell clones. As shown on figure 3 (upper
, the two other T cell clones 1A5 and 5F9 recognized the 11-30 region of MELOE-l, in
a HLA-DR context. The use of HLA-matched B-EBV cell lines allowed to precise that 1A5 T
cell clone was restricted by the B] *1 101 molecule and the 5F9 T cell clone by the
HLA—DR131*0101 molecule.
We further tested the reactivity of these CD4 T cell clones against HLA—matched
melanoma cell lines positive for meloe expression, by qPCR is. All the ma cell
lines tested expressed HLA-DQ and DR at the cell surface. All the T cell clones were reactive
against HLA-matched melanoma cell lines when loaded with the cognate e (Figure3,
lower panel, black bars). The two DQ2-restricted T cell clones were reactive against peptide-
loaded DQBl *0201 and 0202 melanoma cell lines. In absence of peptide, only the 4E2 DQ
131*0201-restricted T cell clone was able to recognize unloaded M77 melanoma cell line (also
DQBl *0201), but not the DQ131*0202 ma cell line, M88. Similarly, the DRl-restricted
T cell clone 5F9 also recognized one ofthe DR131*0101 ma cell line, in the e of
exogenous peptide (M101).
We also documented the T helper profile of each T cell clone, by stimulating the CD4
T cell clones with the cognate peptide, and analyzing cytokine production. All the clones
sed Th1 cytokines (TNFor, IFNy, IL2 and GM-CSF). On the contrary, these clones
differ in their expression of Th2 cytokines. Indeed, the two DQ2 restricted T cell clones
(9C 12 and 4E2) and the DRl restricted one (5F9) also strongly express two Th2 cytokines
(IL4, and IL13), whereas the DRl l-restricted T cell clone only weakly expressed IL4 (Table
IV). None ofthe CD4 T cell expresses ILlO or 1L5 at a significant level.
Processing of the recognized epitopes from autologous DC loaded with MELOE-l
antigen
Initial PBMC stimulation was carried out with MELOE—l whole antigen, and thus we
assume that CD4 T cell responses were generated against peptides naturally processed by
monocytes. Nonetheless, we could not formally exclude that the 14-day culture period
artificially generated shorter class II epitopes that elicited CD4 T cell responses. Thus, it
remained l to assess that all these new epitopes were naturally processed by autologous
dendritic cells loaded with MELOE-l whole protein, in serum-free medium. To this end, we
loaded gous iDC with 1 uM of MELOE—l antigen in serum-free medium, in presence of
maturating agents, and fixed these DC before ation of the CD4 specific T cell . In
these conditions, the four T cell clones were reactive against MELOE-l loaded autologous
DC (Figure 4, left panel), whereas we could not detect any reactivity of CD4 T cell clones to
DC loaded with an irrelevant long peptide, synthesized in the same conditions (Melan—A16_
40L).
As an additional control, we loaded autologous DC with MELOE-l after DC fixation,
and we could observe only a weak recognition by specific CD4 T cell , indicating that
only a small fraction of the protein had been externally degraded into shorter peptides (Figure
4, right panel). Thus, the four new epitopes identified by PBMC stimulation, are naturally
processed from MELOE-l n.
Characterization of the minimal recognized epitopes
Our T cell clones were reactive against 20-mer peptides that are probably not the exact
peptides naturally processed. In order to formally identify the minimal recognized epitopes,
we tested shorter peptides derived from each of the MELOE-l recognized regions, chosen on
the basis of the core peptide ce ed to be recognized by the T cell clones
(indicated in bold on figure 5).
Three shorter peptides were better recognized by the DQ2-restricted 9C12 T cell
clone, the st one being MELOE-17_19 (13-mer), recognized with an ECSO of 100 nM.
The deletion of the two amino acids in C-term strongly reduces T cell clone ition. The
other DQ2-restricted T cell clone (4E2) better recognized a l4-mer peptide (31-44) also with
an ECSO of 100 nM, and also recognized to a lower extent the 32-44 epitope (Figure 5)
previously described in the HLA-DQBI*0603 context (Rogel et al., 2011). Concerning the
DR-restricted T cell clones, optimal shorter es were 13-mer peptides, MELOE-l 15,27 for
the DR131*1101 restricted T cell clone 1A5 (EC50=100 nM), and MELOE-111_23 or MELOE-
112_24 for the DRBl*0101 restricted one e 5). Nonetheless all of these clones recognized
a series of ned peptides, thus we cannot formally assess that the shortest ones will be
the exact es naturally presented on class II molecules.
REFERENCES:
hout this application, various references describe the state of the art to which
this invention pertains. The disclosures of these nces are hereby incorporated by
reference into the present disclosure.
Arden B, Clark SP, Kabelitz D, and Mak TW Human T-cell receptor variable gene
segment families. Immunogenetics 1995; 42: 455—500.
Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, and Heath WR Help for
cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-80.
Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, and van der Burg
SH CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a
vanishing CTL response, whereas long peptides induce ned CTL reactivity. J Immunol
2007; 179: 5033-40.
Chauvin JM, Larrieu P, Sarrabayrouse G, t-Blondel A, Lengagne R,
Desfrancois J, et al. HLA Anchor Optimization of the Melan-A-HLA—AZ Epitope within a
Long Peptide Is ed for Efficient Cross—Priming of Human Reactive T Cells. J
Immunol2012; 188: 0.
Davodeau F, Difilippantonio M, Roldan E, en M, Casanova JL, Couedel C, et
al. The tight interallelic positional coincidence that distinguishes T-cell receptor Jalpha usage
does not result from homologous chromosomal pairing during ValphaJalpha rearrangement.
EMBO J 2001; 20: 4717-29.
Espevik T and Nissen—Meyer J A highly sensitive cell line, WEHI 164 clone 13, for
measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol
Methods 1986; 95: 99-105.
Gervois N, Labarriere N, Le Guiner S, Pandolfino MC, Fonteneau JF, Guilloux Y, et
al. High y melanoma-reactive cytotoxic T lymphocytes are efficiently induced from
peripheral blood lymphocytes on ation by peptide-pulsed melanoma cells. Clin Cancer
Res 2000; 6.‘ 1459-67.
Godet Y, Desfrancois J, Vignard V, Schadendorf D, Khammari A, Dreno B, et al.
Frequent occurrence of high affinity T cells against MELOE-l makes this antigen an
tive target for melanoma immunotherapy. Eur J Immunol 2010; 40: 1786-94.
Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, et a1.
MELOE-l is a new antigen overexpressed in melanomas and involved in ve T cell
transfer efficiency. J Exp Med 2008; 205: 2673-82.
Hunder NN, Wallen H, Cao J, cks DW, Reilly JZ, Rodmyre R, et al. Treatment
of metastatic melanoma with autologous CD4+ T cells against -l. N Engl J Med
2008; 358: 2698-703.
Fayolle C, Deriaud E, and Leclerc C In vivo induction of cytotoxic T cell response by
a free synthetic peptide requires CD4+ T cell help. J l 1991; 147: 4069-73.
Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, et al.
specific CD4+ ma Tumor—infiltrating Lymphocytes. J Immunother 2012.
Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon
AP, et al. Vaccination against HPV-l6 oncoproteins for vulvar intraepithelial neoplasia. N
Engl J Med 2009; 361: 1838-47.
Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, and erg SA le
HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-
infiltrating lymphocytes from a patient with melanoma. J Immun012002; 169: 7.
Rogel A, Vignard V, Bobinet M, Labarriere N, and Lang F A long peptide from
MELOE-l contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201
epitope: an attractive candidate for melanoma vaccination. Cancer Immunol ther
2011; 60: 327-37.
Rosenberg SA, Yang JC, and Restifo NP Cancer immunotherapy: moving beyond
current vaccines. Nat Med 2004; 10: 909-15.
Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J,
et al. gplOO peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J
Med 2011; 364: 2119-27.
Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, et al.
Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol
2004; 5: 1143-8.
ens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua
MG, et al. Induction of p53-specific immunity by a p53 tic long peptide vaccine in
patients treated for metastatic colorectal . Clin Cancer Res 2009; 15: 5.
Toes RE, ga R, Blom RJ, Melief CJ, and Kast WM Peptide vaccination can lead
to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U
S A 1996; 93: 7855-60.
Vesely MD, Kershaw MH, Schreiber RD, and Smyth MJ Natural innate and adaptive
immunity to cancer. Annu Rev l 2011; 29: 235-71.
Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer
DM, et a1. Induction of tumor—specific CD4+ and CD8+ T—cell immunity in cervical cancer
patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer
Res 2008; 14: 178-87.
I
Claims (16)
1. Use of a melanoma antigen peptide of less than 20 amino acids long comprising the amino acid sequence SEQ ID NO:5 in the manufacture of a medicament for the prevention or the treatment of melanoma in a patient.
2. Use of a melanoma n peptide according to claim 1, wherein said peptide is an amino acid ce of less than 15 amino acids long, or wherein said peptide consists of the sequence SEQ ID NO:5
3. Use of a fusion n comprising a melanoma antigen peptide as defined in any one of claims 1 or 2 and a melanoma antigen peptide sing the amino acids motif: - TX2NDECWPX9 (SEQ ID NO: 23) n X2 is leucine, methionine, valine, isoleucine or glutamine and X9 is alanine, valine or leucine in the manufacture of a medicament for the prevention or the ent of melanoma in a patient.
4. Use of a melanoma antigen peptide according to any one of claims 1 or 2 or a fusion protein according to claim 3, n the patient is genotyped with HLA-DQβ1*0201 or HLA- DQβ1*0202 alleles.
5. Use of a T lymphocyte that recognizes specifically a melanoma n peptide as d in any one of claims 1 or 2 in the manufacture of a medicament for the prevention or the treatment of melanoma in a patient.
6. Use of a composition comprising T lymphocytes according to claim 5, wherein said T lymphocytes that recognize specifically a melanoma antigen e or a fusion protein are to be re-administrated to the patient.
7. A method for producing said T lymphocytes as defined in claim 5, said method sing the steps of: (a) stimulating PBMCs or tumor infiltrating cytes obtained from a patient with at least one melanoma antigen peptide according to any one of claims 1 or 2 or a fusion protein according to claim 3, (b) enriching the population of T lymphocytes specific for the melanoma antigen peptide(s) used in (a), (c) optionally cloning said population of T lymphocytes specific for the melanoma antigen peptide(s) used in (a).
8. A ma antigen peptide comprising the amino acid sequence SEQ ID NO:5, wherein said peptide has an amino acid sequence of less than 15 amino acids long, or consists of the sequence SEQ ID NO:2 or SEQ ID NO:4.
9. A melanoma antigen peptide according to claim 8, wherein said peptide consists of any one of the sequences SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:5.
10. A fusion protein comprising a melanoma n peptide as defined in any one of claims 8 or 9 and a melanoma antigen peptide comprising the amino acids motif: AH26(12781302_1):EOR - TX2NDECWPX9 (SEQ ID NO: 23) wherein X2 is leucine, methionine, valine, isoleucine or glutamine and X9 is alanine, valine or leucine.
11. A nucleic acid sequence ng a melanoma antigen e according to any one of claims 8 or 9 or a fusion protein according to claim 10.
12. An expression vector comprising a nucleic acid sequence according to claim 11.
13. A host cell comprising an expression vector according to claim 12, n the host cell is not within a human body.
14. An antibody or fragment thereof that binds to a melanoma antigen peptide according to any one of claims 8 or 9.
15. An immunising composition comprising: (a) at least one ma antigen peptide according to any one of claims 8 or 9 or (b) at least one fusion protein according to claim 10, or (c) at least one nucleic acid sequence according to claim 11 or (d) at least one sion vector ing to claim 12, or (e) at least one host cell according to claim 13, or (f) at least one antibody according to claim 14.
16. Use of an antibody or fragment thereof that binds to a melanoma antigen peptide as defined in any one of claims 1 or 2 in the manufacture of a medicament for the prevention or the treatment of ma in a patient.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2012/001310 WO2013175256A1 (en) | 2012-05-22 | 2012-05-22 | Novel melanoma antigen peptide and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ701000A NZ701000A (en) | 2017-03-31 |
NZ701000B2 true NZ701000B2 (en) | 2017-07-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230414735A1 (en) | Neoantigens and methods of their use | |
TWI730306B (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
EP3140319B1 (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) | |
US6602510B1 (en) | HLA class I A2 tumor associated antigen peptides and vaccine compositions | |
TWI670282B (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
JP5502823B2 (en) | Proteins belonging to the BCL-2 family and fragments thereof, and their use in cancer patients | |
US20160022791A1 (en) | Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Cancer | |
US20080279924A1 (en) | HLA class I A2 tumor associated antigen peptides and vaccine compositions | |
JP2021527426A (en) | Neoantigen and its use | |
CA2661651A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
JP6523685B2 (en) | Native and agonist CTL epitopes of MUC1 tumor antigen | |
JP2021527655A (en) | Neoantigens and their use | |
CA2393730A1 (en) | Hla class i a2 tumor associated antigen peptides and vaccine compositions | |
US9475841B2 (en) | Melanoma antigen peptide and uses thereof | |
US10898562B1 (en) | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | |
US20030224036A1 (en) | Hla class I a2 tumor associated antigen peptides and vaccine compositions | |
US9573975B2 (en) | Melanoma antigen peptide and uses thereof | |
JP2020014460A (en) | Novel immunotherapy for several tumors of blood, in particular chronic lymphatic leukemia (cll) | |
US20160331818A1 (en) | Novel antigen peptide and uses thereof | |
NZ701000B2 (en) | Novel melanoma antigen peptide and uses thereof |